Katherine Glaser, MD, MPH is an Obstetrician/Gynecologist who has worked on the Navajo Nation for 10 years. Dr. Glaser completed her medical school and residency training at the University of Arizona and training in clinical research at the University of California Davis. Her clinical and research interests include improving care related to hypertension and diabetes in pregnancy.
Combating Maternal Morbidity & Mortality as a State
Thursday, Sept. 22, │ 1:15 p.m.
Facilitated by Andrew F. Rubenstein, M.D., FACOG and co-presenting with Stacie Wood
Maternal mortality and morbidity is a growing concern for U.S. hospitals and communities. Each year, 50,000 people suffer a severe maternal complication, which in fact is higher in people of color. Annually, 700 people die from giving birth. Obstetrics remained the only service line open throughout the COVID-19 pandemic. It highlighted the opportunity hospitals now have to dig into the root causes of poor maternal health, especially in rural communities. Poor maternal health outcomes are rooted in complex, pre-existing clinical conditions, access to maternity services, societal factors and structural racism.
In this dialogue, learn about the AIM Collaborative, consisting of 34 Arizona hospitals coming together to apply evidence-based practices to combat pregnancy-related deaths and underlying factors associated with it. Experts will share steps they are taking to reach the collaborative’s goal of reducing complications of hypertension by 20% before the end of 2022. Additionally, hear from participating hospitals about their health equity efforts, as they navigate ways to identify and address disparities and gaps in culturally appropriate maternal care.
Maternal Anti-Hypertensive Drugs: Ask the Experts!
Thursday, Sept. 22, │ 2 p.m.
Facilitated by Andrew F. Rubenstein, M.D., FACOG and co-presenting with Sarah Basinger, RN, BSN, MHI, Cathleen Harris, M.D., MPH, Cheryl K. Roth, Ph.D., WHNP-BC, RNC-OB, RNFA, and Stacie Wood, MSN
Expert panelists come together to address roadblocks to medication utilization. In this Q&A style session, attendees will have the opportunity to ask questions and discuss barriers in achieving the AIM goal of hypertensive treatment in under 60 minutes.